AlphAIalphai — Financial news for AI agents
forbes.comAUG 293 min read

Suja Life’s Recent Volatility Masks A Longer Game In Functional Beverages

Suja Life's stock fell to $9 from $18 after lowering full-year guidance due to grocery channel weakness. Investors are exploring lawsuits, citing potential misleading information. Despite Q2 sales growth of 11.6% to $83.9M, sequential sales dropped 21%. The company remains optimistic about its long-term strategy in the functional beverage market, which is expected to reach $400B by 2034.

Original reporting
forbes.com
Published Aug 29, 2026, 3:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 29, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Suja Life’s Recent Volatility Masks A Longer Game In Functional Beverages — source image
Source · forbes.com
Decision brief

The 30-second read

Med
01

Why it matters

The earnings miss and guidance cut are fresh disclosures that materially affect valuation; the stock has already halved, indicating high sensitivity.

02

Market read

The earnings surprise and guidance downgrade drive immediate price action and may influence sentiment toward other niche beverage stocks.

03

What to watch

Seasonality of sales and upcoming holiday demand could improve top‑line, mitigating the guidance cut.

Relevance 7/10Novelty 8/10Timing: post‑earnings release today

Background

Suja Life, a cold‑pressed juice and wellness‑shot specialist, reported Q2 results with a revenue miss and a significant net‑loss increase, prompting a downward revision of FY guidance.

Market effects

Sector

Highlights weakness in grocery channel for functional beverage pure‑plays, may pressure peers like Oatly and Lifeway.

Regional

U.S. consumer discretionary segment sees heightened scrutiny on health‑focused brands.

Global

Signals broader caution for functional beverage category growth forecasts.

Counterpoint

What could challenge this read

If the company can successfully shift sales to convenience and airport channels, the current dip may be over‑priced.

Key entities

  • company
    Suja Life Inc.

    Public functional‑beverage company reporting Q2 earnings.

  • executive
    Maria Stipp

    CEO of Suja Life, provided guidance and commentary.

Read at source← All news

Related articles

AUG 6
$SUJAMed

Suja Defies Grocery Slowdown With Double-Digit Sales Growth in Q2

Suja Life, Inc. (Nasdaq: SUJA) reported Q2 net sales up 11.6% year over year to $83.9 million, citing volume growth and improved distribution. Gross profit increased 9.9% to $39.2 million, or 46.7% of sales. The company raised its 2026 outlook to $360 to $369 million net sales from $326.6 million in 2025.

yahoo.com2 min
AUG 4
$SUJAMed

SUJA LIFE, INC. (SUJA): Results of Operations and Financial Condition

SUJA LIFE, INC. (SUJA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Suja Life Reports Second Quarter 2026 Financial Results Net sales increased 11.6% year-over-year to $83.9 million Updates fiscal year 2026 outlook OCEANSIDE, CA, August 4, 2026 – Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life,” “Suja” or the “Company”), a leading better-for-you bever

SEC EDGAR 8-K6 min
JUN 9
$SUJAMedAI 9/10

Suja Life Reports First Quarter 2026 Financial Results

Suja Life (NASDAQ: SUJA) reported first-quarter 2026 net sales of $107.1 million, up 22.5% year over year from $87.4 million. Adjusted EBITDA rose 66.3% to $25.0 million, with margin expanding to 23.4%. Net income was $7.7 million versus a prior-year net loss. The company initiated 2026 guidance: net sales $367–$371 million and Adjusted EBITDA $70–$72 million.

manilatimes.net7 min
JUN 3
$SUJAMed

Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore

Evercore upgraded Suja Life (NASDAQ:SUJA) to a “strong-buy” rating in a Monday research note, according to Zacks.com. Other firms also initiated coverage: Goldman Sachs set a $31 target and a “buy,” Jefferies set a $25 target and a “buy,” and William Blair rated “outperform.” MarketBeat data show a consensus “Buy” and average target $26.67.

themarketsdaily.com2 min
JUN 1
$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.

cnbc.com6 min
AUG 29
$CRWDHighAI 9/10

CrowdStrike's AI bet just paid off in a big way

CrowdStrike Holdings (CRWD) reported strong fiscal Q2 results, with revenue of $1.47B (+26% YoY) and adjusted earnings of $0.31/share, beating estimates. The company raised its full-year revenue forecast to $5.99B-$6.01B and increased net new ARR growth guidance to 34%. Shares surged 20.5% after earnings. Analysts cited AI-driven demand as a key growth driver, with multiple firms raising price targets. Rival Palo Alto Networks (PANW) also gained 13%.

yahoo.com2 min
Suja Life’s Recent Volatility Masks A Longer Game In Functional Beverages — alphai